Table 1. Characteristics of the patients at diagnosis.
| Characteristics | All (n = 25) | PET2– (n = 19) | PET2+ (n = 6) |
|---|---|---|---|
| Age, years, median (range) | 68 (39–83) | 68 (39–83) | 69 (57–79) |
| Age < 60 | 8 (32%) | 6 (32%) | 2 (33%) |
| Male sex | 9 (36%) | 7 (37%) | 2 (33%) |
| PS (ECOG) | |||
| 0 | 5 (20%) | 4 (21%) | 1 (17%) |
| 1 | 6 (24%) | 3 (16%) | 3 (50%) |
| ≥2 | 14 (56%) | 12 (63%) | 2 (33%) |
| IESLG risk group* | |||
| Low | 1 (4%) | 1 (5%) | 0 (0%) |
| Intermediate | 12 (48%) | 8 (42%) | 4 (67%) |
| High | 12 (48%) | 10 (53%) | 2 (33%) |
| MSK score | |||
| 1 | 2 (8%) | 2 (11%) | 0 (0%) |
| 2 | 10 (40%) | 6 (32%) | 4 (67%) |
| 3 | 13 (52%) | 11 (58%) | 2 (33%) |
| Positive CSF cytology#,* | 1 (8%) | 0 (0%) | 1 (17%) |
| Ocular involvement§,* | 1 (11,1%) | 0 (0%) | 1 (17%) |
| Germinal center type | 7 (28%) | 5 (26%) | 2 (33%) |
| Non germinal center type | 18 (72%) | 14 (74%) | 4 (67%) |
PS: performance status; ECOG: Eastern Cooperative Oncology Group; IESLG: international extranodal lymphoma study group; MSK: Memorial Sloan-Kettering Cancer Center; CSF: cerebrospinal fluid; GC: germinal center; non-CG: non germinal center DLBCL subtypes. *Data regarding CSF protein concentration were available in 14 patients. When missing, this data was considerate as elevated for the IESLG risk group assessment. #available for 12 patients at diagnosis; §available for 9 patients at diagnosis; *Absence of CSF and ocular involvement were excluded in all patients without initial evaluation during follow up.